Cardiovascular Systems, Inc. Announces Date of Its Annual Meeting of Stockholders & Deadlines for Submitting Stockholder Prop...
September 09 2010 - 4:05PM
Business Wire
Cardiovascular Systems, Inc. (Nasdaq: CSII) today announced that
it will hold its Annual Meeting of Stockholders at 10:00 a.m.,
Central Standard Time, on Thursday, November 18, 2010, at the
company’s offices, located at 651 Campus Drive, St. Paul, Minnesota
55112. Stockholders of record as of the close of business on
September 23, 2010 are entitled to notice of and to vote at the
Annual Meeting.
Rule 14a-8 Stockholder Proposal Deadline
The Annual Meeting date represents a change of more than 30 days
from the anniversary of the company’s last annual meeting of
stockholders. As a result, pursuant to Rule 14a-8 under the
Securities Exchange Act of 1934, as amended, the company has set a
new deadline for the receipt of any stockholder proposals submitted
pursuant to Rule 14a-8 for inclusion in the company’s proxy
materials for the Annual Meeting. The new deadline for the
submission of stockholder proposals is the close of business on
September 24, 2010. Such proposals should be delivered to:
Cardiovascular Systems, Inc., 651 Campus Drive, St. Paul, Minnesota
55112, Attention: Secretary. The company recommends that such
proposals be sent by certified mail, return receipt requested. Such
proposals will also need to comply with the rules of the Securities
and Exchange Commission regarding the inclusion of stockholder
proposals in the company’s proxy materials and may be omitted if
not in compliance with applicable requirements.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a
medical device company focused on developing and commercializing
interventional treatment systems for vascular disease. The
company’s Diamondback 360® and Diamondback Predator 360™ PAD
Systems treat calcified and fibrotic plaque in arterial vessels
throughout the leg in a few minutes of treatment time, and address
many of the limitations associated with existing surgical, catheter
and pharmacological treatment alternatives. As many as 12 million
Americans suffer from peripheral arterial disease (PAD), which is
caused by the accumulation of plaque in peripheral arteries
(commonly the pelvis or leg) reducing blood flow. Symptoms include
leg pain when walking or at rest, and can lead to tissue loss and
eventually limb amputation. In August 2007, the U.S. FDA granted
510(k) clearance for the use of the Diamondback 360° as a therapy
for PAD, and CSI commenced a U.S. product launch in September 2007.
Since then, nearly 30,000 procedures have been performed using the
Diamondback 360° in leading institutions across the United States.
For more information visit the company’s Web site at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From May 2024 to Jun 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2023 to Jun 2024